Clinical bottom line
Comorbidities significantly influence treatment decisions and outcomes in older cancer patients, necessitating comprehensive assessment beyond chronological age. Incorporating multidimensional evaluations of vulnerabilities, including frailty and organ dysfunction, improves therapy personalization and may enhance survival and quality of life. Recent guidelines emphasize systematic assessment and tailored management to balance treatment efficacy with tolerability in this population.
What the evidence shows
The ASCO guideline update by Dale et al. (2023) provides practical recommendations for assessing vulnerabilities in older adults receiving systemic cancer therapy. They advocate for routine use of geriatric assessment tools to identify comorbidities, functional impairments, and psychosocial factors that impact treatment tolerance and outcomes. This approach supports individualized treatment planning and toxicity mitigation.
Sekeres et al. (2026) present the American Society of Hematology’s guidelines for treating older adults with acute myeloid leukemia, highlighting the importance of comorbidity evaluation in guiding intensity of therapy and supportive care. Their recommendations underscore that comorbidities influence both treatment selection and prognosis.
Paappanen et al. (2025) retrospectively analyzed elderly patients with non-small cell lung cancer, demonstrating that comorbidities affected treatment decisions and were independently associated with survival outcomes. Patients with fewer or well-managed comorbidities were more likely to receive curative-intent therapies and had improved survival.
Upshaw et al. (2024) studied older patients with Hodgkin lymphoma and preexisting heart failure, finding that cardiac comorbidity led to modified treatment regimens and was linked to worse outcomes. This highlights the need for careful cardiovascular assessment and multidisciplinary management.
Yip et al. (2024) reported that frailty and comorbidities in lung cancer patients influenced treatment intensity and were predictive of both toxicity and survival, reinforcing the prognostic value of comprehensive patient evaluation.
Older studies such as Bailey et al. (2003) remain relevant by demonstrating that multidimensional function assessments, including comorbidity burden, better predict treatment decisions than age alone in colorectal cancer patients.
George et al. (2020) systematically reviewed physical comorbidities’ impact on cancer treatment and outcomes in older adults, concluding that comorbidities are associated with treatment modifications, increased toxicity, and poorer survival, but heterogeneity in study designs limits definitive conclusions.
Caveats and uncertainty
Many studies are retrospective or observational, limiting causal inference.
Variability in comorbidity measurement tools and frailty definitions complicates comparisons.
Data on the impact of specific comorbidities across diverse cancer types and treatments remain limited.
The balance between undertreatment and overtreatment in the context of comorbidities is challenging.
Prospective trials incorporating standardized geriatric assessments are needed to guide evidence-based interventions.
How this may change practice
Routine implementation of geriatric assessment tools to evaluate comorbidities and vulnerabilities should be standard in oncology care for older adults.
Treatment plans should be individualized considering comorbidity burden, functional status, and patient preferences.
Multidisciplinary collaboration, including cardiology and geriatrics, can optimize management of comorbid conditions.
Enhanced supportive care and toxicity monitoring may improve treatment adherence and outcomes.
Future clinical trials should stratify by comorbidity status to generate more applicable evidence for this population.